Summit Therapeutics Inc.
SMMT
$26.20
$0.190.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 410.83M | 64.23M | 60.16M | 57.29M | 42.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 59.00K | 59.00K | 59.00K | 85.00K | -444.00K |
| Total Operating Expenses | 759.28M | 235.45M | 210.99M | 181.59M | 143.70M |
| Operating Income | -759.28M | -235.45M | -210.99M | -181.59M | -143.70M |
| Income Before Tax | -746.08M | -240.76M | -221.32M | -196.68M | -161.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -746.08 | -240.76 | -221.32 | -196.68 | -161.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -746.08M | -240.76M | -221.32M | -196.68M | -161.69M |
| EBIT | -759.28M | -235.45M | -210.99M | -181.59M | -143.70M |
| EBITDA | -759.18M | -235.37M | -210.90M | -181.49M | -143.59M |
| EPS Basic | -1.01 | -0.33 | -0.31 | -0.28 | -0.23 |
| Normalized Basic EPS | -0.63 | -0.19 | -0.18 | -0.16 | -0.13 |
| EPS Diluted | -1.02 | -0.35 | -0.32 | -0.28 | -0.23 |
| Normalized Diluted EPS | -0.63 | -0.19 | -0.18 | -0.16 | -0.13 |
| Average Basic Shares Outstanding | 2.94B | 2.91B | 2.87B | 2.84B | 2.81B |
| Average Diluted Shares Outstanding | 2.94B | 2.91B | 2.87B | 2.84B | 2.81B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |